January 8 – 11, 2018 J.P. Morgan 36th Annual Healthcare Conference 2018 San-Francisco The annual J.P. Morgan Healthcare Conference is the largest and most…
Invectys announces FDA approval to launch a Phase II clinical trial of its therapeutic cancer vaccine INVAC-1 After a recent capital raise of 4.3 M€s another…
Après le succès de sa Phase I, Invectys lève 4.3 Millions d’Euros permettant la rentrée en Phase II de ses deux vaccins anticancéreux Paris, le 12…
The immune system is able to recognize tumor cells and destroy them…
The telomerase enzyme functions as part of a large ensemble of proteins and RNA called the telomerase ribonucleoprotein complex.…
Monoclonal antibodies targeting checkpoint inhibitors are hugely important immunotherapy molecules for the treatment cancers…
